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http://www.biomedcentral.com/1471-2407/13/249RESEARCH ARTICLE Open AccessNuclear TK1 expression is an independent
prognostic factor for survival in pre-malignant
and malignant lesions of the cervix
Gang Chen1*, Cheng He1, Ling Li2, An Lin2, Xiongwei Zheng1, Ellen He3 and Sven Skog3*Abstract
Background: Thymidine kinase 1 (TK1) is a proliferation biomarker that has been found useful for prognostication
in cancer patients. Here we investigate for the first time the use of TK1 expression as a prognostic factor for
patients with premalignant and malignant lesions of the uterine cervix.
Methods: TK1 expression was determined by immunohistochemistry in cervical lesions (cervical intraepithelial
neoplasia (CIN), n = 216; invasive cervical carcinoma, n = 84). TK1 and Ki-67 expressions and pathological/FIGO stages
and age were correlated with 5-year survival by Kaplan-Meier, log rank and COX hazard uni- and multivariate analyses.
Results: TK1 labeling index (LI) was significantly correlated with CIN grades and invasive cervical carcinoma stages, while
TK1 labeling intensity was only correlated to CIN grades. TK1 LI was significantly higher compared with Ki-67 LI. TK1 LI
correlated significantly to 5-year survival in patients with invasive cervical carcinoma, particularly nuclear TK1 LI. In a
multivariate analysis, nuclear TK1 expression was independent prognostic factor in patients with in situ/invasive cervical
carcinoma or in invasive cervical carcinoma alone. Interestingly, in invasive cervical carcinoma patients with advanced
tumors, nuclear TK1 expression could identify patients with significantly better survival rates (80%), while Ki-67 could not.
Conclusions: Nuclear TK1 expression in early grade CIN predicts risk for progression to malignancy. Nuclear TK1
expression is also a prognostic factor for treatment outcome, particularly in patients with advanced cervical carcinomas.
Nuclear TK1 expression is more useful than Ki-67 and pathological/FIGO stages.
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Cervical cancer is the third most common malignancy
in women and a major cause of morbidity and mortality,
particularly in developing countries [1]. However, in in-
dustrial countries, the incidence and mortality rates of
cervical cancer are decreasing [2]. A Hong Kong based
study reported in 2011 an overall 5-year survival rates of
90.9%, 71.0%, 41.7% and 7.8%, respectively in FIGO
stages I, II, III, and IV of invasive cervical cancer [2]. Pa-
tient age, FIGO stage and histology were independent
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has a potential risk of progression to invasive cervical
carcinomas, in particular [3]. Therefore, much research
has focused on the eradicating of CIN to prevent devel-
opment of invasive cancer.
The Pap test smear (cervical cytology smear) has been
widely used for detection of CIN and cervical cancer. An
human papilloma virus (HPV) intervention trial screen-
ing study has shown on HPV DNA testing to permit
earlier detection of clinically relevant CIN grade II,
which, when adequately treated, should improve protection
against progression to CIN grade III or cervical cancer
[4,5]. Although HPV infection is regarded as the main etio-
logic factor for the development of cervical carcinoma,
cell proliferation or apoptosis does not correlate with the
level of HPV infection [6]. However, the proliferation
marker Ki-67 and/or p16 showed correlation with CINtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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detection of dual p16/Ki-67 nuclear immune-reactivity in a
liquid-based Pap test has been introduced for the analysis
of cervical lesions [10].
Recently a cell cycle–dependent marker, thymidine
kinase 1 (TK1), has been introduced to evaluate tumor
proliferation by immunohistochemistry. A basic study
on the expression of TK1 and Ki-67 demonstrated acti-
vated G1 cells to show higher TK1 expression compared
with Ki-67 [11]. A highly specific TK1 monoclonal anti-
body developed by our laboratory has been used to assess
the proliferation rate of benign, pre-malignant and malig-
nant cells in breast [12] and prostate lesions [13,14]. TK1
was also more sensitive than Ki-67 in cancer patients with
prostate [13] and ovary [15] carcinomas. Higher TK1
expression was found in clear cell and papillary renal
cell carcinomas (RCC) compared with oncocytomas and
normal kidney [16]. Higher expression of TK1 in pros-
tate carcinoma was associated with a shorter interval to
recurrence and development of metastasis [14]. Further-
more, TK1 expression was an independent prognostic fac-
tor for pathological T1 (pT1) lung adenocarcinoma [17]. In
the pT1 patients with stromal invasion grade III, low TK1
level was correlated with good survival. The intensity of
TK1 staining was found to be a prognostic factor in RCC
patients [18]. Furthermore, the serum TK1 level is a useful
marker for prognostication and monitoring of cancer treat-
ment, as well as serving as a potential biomarker for early
detection of cancer in health screening setting [19-21].
To date, no studies have been performed on TK1 ex-
pression in premalignant and malignant cervical lesions.
This study aimed to determine TK1 expression in these
lesions and its correlation with outcome. TK1 was found




Specimens were collected from a cohort of 2,840 pa-
tients with uterine cervical lesions treated at Fujian Pro-
vincial Tumor Hospital, China, from January 2006 to
December 2009. Invasive carcinoma account for a high
proportion of the cervical lesions because the hospital is
an Oncology Center. From this cohort, 300 specimens
were randomly selected (CIN I, n = 78; CIN II, n = 64;
CIN III, n = 74; invasive cervical squamous cell carcinoma,
n = 84). All specimens were formalin-fixed and paraffin-
embedded. The histology and diagnosis confirmed on
hematoxylin-stained sections. The lesions were classified
according to the International Federation of Gynecology
and Obstetrics (FIGO) [22] and the International Union
Against Cancer (UICC) TNM staging system [23]. The
characteristics of the patients are shown in Table 1. In the
following text the CIN III/carcinoma in situ/pathologicalstage 0 group is denoted as “CIN III”. Since the number of
the invasive cervical carcinoma patients of pathological
stages I was low (n = 3), this group of patients was com-
bined with stage II group (n = 47) for analysis.
The number of CIN patients in the cohort studied
was about 20%, which is less than expected. The rea-
son is that this study was performed at an oncology
clinic and not at a health center, where the majority of
CIN pre-malignancy cases are discovered. Patients with
CIN, even CIN III, are not strongly recommended to visit
an oncology clinic for further investigation and treatment.
However, when the symptoms are obvious, i.e. progress
into cervical carcinoma, these patients contact the onco-
logy clinic.
Study design
The study was to investigate the value of TK1 expression
in cervical lesions (CIN and invasive cervical carcinoma)
for prognostication. This was performed by determining
the LIs of TK1 and Ki-67 in relation to survival. In the
first analysis, TK1 expression in tumor cells (total; cyto-
plasmic; cytoplasmic+nuclear; intensity) was determined
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III and invasive cervical carcinoma, as one group. Ki-67
expression and survival rates of the patients of different
pathological/FIGO stages were used as controls. In the
second analysis, TK1 expression was analyzed in relation
to 5-year survival of invasive cervical carcinoma patients
with advanced tumors (pathological stage III/FIGO
stages IIA – IV). Ki-67 expression and pathological
stage IIB/FIGO stage IA, IB and IIA were used as
controls. The end-points were the number of deceased
patients and the 5-year survival rates. The variables
considered were CIN grades, tumor pathological stages,
FIGO stages, age, TK1 labeling index (LI) of whole
tumor cell, cytoplasmic/nuclear TK1 LI, TK1 intensity
and Ki-67 LI. Three hundred specimens were studied
to allow for adequate statistical analysis.
Treatment
Patients treatment was in accordance with recommenda-
tions of the FIGO [22]. Briefly, patients with CIN I (n = 78)
were checked once per year and were not treated. Patients
with CIN II (n = 64) were treated by LEEP (loop electrosur-
gical excision procedure) procedure or laser surgery, while
patients with CIN III (n = 74) were treated by surgery.
Patients with invasive cervical carcinoma (n = 84) received
surgical treatment combined with chemotherapy/radio-
therapy according to the FIGO guidelines [22].
Follow-up information
In total, 106 patients (CIN III, n = 45; invasive cervical
carcinoma pathological stage II (n = 28), III (n = 33) or
FIGO stages IA+IIA (n = 13), and IIB+IV (n = 48) were
followed-up over 5 years using information obtained
from the medical records and telephone contacts. Infor-
mation was collected from 4th January 2006 to 23rd April
2012. The CIN patients with stages I and II were also
followed up for 5 years, but no death were reported, and
thus no statistical COX analysis could be performed.
Immunohistochemical staining
Immunohistochemical staining was carried out using the
EnVision System according to the manufacturer’s in-
structions (Maxin Biotech, Fuzhou, China), as previously
described [12,17]. In brief, two serial sections were used
for the staining of human TK1 monoclonal antibody
(800 × PBS dilution of 1 mg/ml, SSTK Biotech. Ltd.,
Shenzhen, China) and Ki-67 mAb (MIB-1, 50 mg IgG1/l,
Dako, Copenhagen, Denmark), respectively. The anti-
TK1 monoclonal antibody has previously been quality
controlled and characterized [12]. The quality of the
TK1 monoclonal antibody used in this study was also
confirmed by independent research groups [14,16,18,21].
At least 100 lesional cells were counted in approxi-
mately 10 microscopic fields at a magnification of x 400.The expression of TK1 and Ki-67 were determined by
the percentage of stained cells, denoted as labeling index
(LI). The LI of TK1 was assessed as “total TK1” (TK1
was expressed in the cytoplasm alone and in both the
cytoplasm and nucleus). The “cytoplasmic and nuclear
TK1” refers to simultaneous TK1 expression in the cyto-
plasm and nuclei. The LI of Ki-67 was determined as the
percentage of cells with nuclear staining. In addition to
LI, the intensities of the staining of TK1 were deter-
mined by a semi-quantitative score system described by
Gakis et al. [18]. Briefly, the TK1 intensities were checked
visually at a magnification of x 160 and divided into four
groups denoted 0, 1, 2 and 3. Examples of the TK1 inten-
sities are shown in Figure 1A. The intensity of Ki-67 was
also evaluated. However, since there was no change in the
intensity of Ki-67 it was not evaluated in detail. One
pathologist (Cheng He) determined the expression of TK1
and Ki-67 LI twice and the results were re-checked once
by a second pathologist (Gang Chen). The counting was
performed blind.Statistical analysis
Statistical significance was calculated by two-tailed
t-tests (SPSS Statistics V17.0, IBM, USA) and Chi-square
test by correlation-Pearson test (Analysis-it, UK). Kaplan–
Meier and log-rank tests (SPSS Statistics V17.0, IBM) were
used when calculating the statistical significances of the
survival rates, while COX regression analysis was used for
the uni- and multivariate analysis (SPSS Statistics V17.0,
IBM). When p-values were > 0.05 no data was given on
the hazard ratios and 95% confidence interval (CI) by the
statistical program (SPSS Statistics V17.0, IBM). P-values
of < 0.05 were considered statistically significant.
ROC analysis (Analysis-it, UK) was used when deter-
mining the cut-off values of the LI of TK1 and Ki-67.
The cut-off value of total TK1 LI was set to 70.0% (ROC-
value 0.86, p < 0.0001), cytoplasm and nuclear TK1 to
50.0% (ROC-value 0.81, p < 0.0001) and Ki-67 to 55.0%
(ROC-value 0.81, p < 0.0001). Patients with a LI below the
cut-off values were denoted as “low” and above the cut-off
value as “high” (Figure 2).
The study was approved by the Committee of Re-
search Ethics at Fujian Provincial Cancer Hospital and
Teaching Hospital of Fujian Medical University, Fuzhou,
Fujian, China. All the patients gave informed consent to
participate in this study, which was conducted in accor-
dance with the Helsinki Declaration of 1983.Results
LI of TK1 and Ki-67
The LI of TK1 and Ki-67 are shown in Table 2. While Ki-67
was exclusively found in the nuclei of cells (Figure 1A), TK1
was expressed in both the cytoplasm and nuclei, or in
Figure 1 TK1 and Ki-67 immunohistochemistry staining of CIN and invasive cervical carcinomas. A) Example of TK1 and Ki-67
immunohistochemistry staining of CIN I, CIN II, CIN III and invasive cervical carcinomas (CA). The intensity (Int.) of the TK1 staining was scored as
0, 1, 2, and 3. Red arrows indicate cells with cytoplasmic TK1 staining only; yellow arrows indicate cells with both cytoplasmic and nuclear TK1
staining. Magnification x 400. B) Relative number of CIN and invasive cervical carcinoma patients with various TK1 staining intensities.
C) Correlation between TK1 LI and TK1 intensity of CIN I to III lesions and of invasive cervical carcinomas with pathological stages II and III.
Pearson-correlation statistical values are shown (r = regression coefficient).
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only TK1 in the nuclei (Figure 1A).
For CIN lesions, the LI of total TK1, cytoplasmic and
nuclear TK1, and Ki-67 increased significantly from CIN
grade I to grade III (Table 2). In patients with invasive
cervical carcinoma, only the LI of total TK1 increased
significantly, compared with CIN III (Table 2). The LI of
TK1 was significantly higher compared with the LI of
Ki-67 (p > 0.05). The ratio between the TK1 expression
in the cytoplasmic and nuclear group and the total TK1
group increased from CIN grade I to grade III (I = 0.42,
II= 0.61, III= 0.67), but did not increase further in
the invasive carcinoma pathological stages II and III
(II = 0.63, III = 0.66).
Intensity of TK1 and Ki-67 expression
The intensity of TK1 expression increased significantly
from CIN I to CIN III and from CIN III to the invasive
cervical carcinoma pathological stage II/FIGO stage IA +
IIA, but did not increase further in the advanced tumor
stages (Table 3). There were no changes in the intensity
of the Ki-67 staining among CIN grades and stages of the
invasive cervical carcinoma (Figure 1A). However, there
was a correlation between changes of TK1 LI and TK1intensities in both CIN and invasive cervical carcinoma
patients (Figure 1C).
Survival of patients in relation to pathologic and
FIGO stages
Of the patients with CIN III, and pathological stages II
and III cervical carcinoma, 19.8% (21/106) died during
the 5 year follow-up period, of which only two patients
with CIN III died. Both of these patients showed a total
TK1 LI of 80% and cytoplasmic/nuclear TK1 LI of 60%.
The TK1 intensity score was 3. The LI of Ki-67 were
83% and 3%, respectively. One of the patients died at
31 months and the other at 47 months.
The 5-year survival rate of the CIN III patients was
95.6%, while that of patients with pathological stages II
and III were 75.0% and 64.7%, respectively. Kaplan–
Meier survival curves and log-rank test showed that the
survival of the CIN III patients was significantly better
compared to the invasive cervical carcinoma patients
with pathological stage II (X2 = 12.5, p < 0.0001) and III
(X2 = 7.3, p = 0.007) (Figure 2A). There was no signifi-
cantly difference in the survival between pathological
stage II and III of the invasive cervical carcinoma pa-
tients (X2 = 0.9, p = 0.339) (Figure 2A). Using the FIGO
Figure 2 Five-year survival of CIN III and invasive cervical carcinoma patients in relation to LI. (A) Five-year survival rate of pathological
stages 0 to III (0 solid line, II dotted line and III dashed line) and (B) FIGO stages 0 to IV (0 solid line, IA to IIA dotted line and IIB to IV dashed line)
of CIN III and invasive cervical carcinoma patients combined (n = 106). Five-year survival rate in relation to LI of Ki-67 (C), total TK1 (D),
cytoplasmic/nuclear TK1 (E), TK1 intensity (F), TK1 cytoplasmic and nuclear of pathological stage III (n = 33) (G) and FIGO stage IIB to IV (H). Low
LI (solid line) and high LI (dotted line). The TK1 intensity (F) was scored as 1 (solid line), 2 (dotted line) and 3 (dashed line). Significant log rank
values between the survival curves are shown. The solid dots in the survival curves show the times of censored observations.
Table 2 Labeling index (LI) in relation to grades of CIN and stages of invasive cervical carcinoma
Type Grade/stage No TK1 total* P TK1 cyto + nucl** P Ki-67 P
CIN Grade I 78 17.5±16.7 7.3±11.2 10.8±13.0
<0.0001 <0.0001 <0.0001
Grade II 64 37.2±22.9 22.1±18.7 26.5±21.2
<0.0001 <0.0001 <0.0001
Carcinoma in situ Grade III 74 54.6±20.5 36.6±18.9 43.9±23.1
(CIN III)
0.001 0.041 <0.0001
Invasive CA Stage II 50 66.6±17.8 43.5±18.4 60.5±23.1
0.029 0.117 0.701
Stage III 34 74.9±15.4 49.7±18.4 62.5±23.2
*TK1 expression in cytoplasm alone + TK1 expression in both cytoplasm and nuclear; ** TK1 expression in cytoplasm + nuclear; No = number of patients.
CA = carcinoma.
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Table 3 Number of patients with low (score 0 and 1) or
high (score 2 and 3) TK1 intensity in relation to CIN and
invasive cervical carcinoma (CA)
Type Grade/stage Low High P
CIN Grade I 48 30
0.024
Grade II 22 42
0.012
Cancer in situ Grade III 12 62
0.026
Invasive CA Stage II 2 48
0.83
Stage III 1 33
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at FIGO 0, 69.2% at FIGO IA+IIA and 64.5% at FIGO
IIB+IV (Figure 2B). Kaplan-Meier survival curves and
log rank tests showed a significant difference in the sur-
vival rate for FIGO stage 0 patients versus FIGO IA+IIA
(X2 = 13.2, p < 0.0001) or versus IIB+IV (X2 = 9.5,
p = 0.002) (Figure 2B). No significant difference was
found between patients with FIGO IA+IIA versus IIB+IV
(X2 = 0.5, p = 0.472) (Figure 2B).TK1 and Ki-67 in relation to survival
Death of CIN III and invasive cervical carcinoma patients
The percentage of deceased patients in the low and high
total TK1 LI was 9.0% and 38.5%, respectively (X2 = 8.6,
p = 0.003), while the corresponding values for the cyto-
plasmic/nuclear TK1 LI was 9.2% and 46.7%, respec-
tively (X2 = 11.4, p < 0.001). The percentages of deceased
patients with low and high Ki-67 LI groups were 12% and
31%, respectively (X2 = 4.1, p = 0.042).Survival of CIN III and invasive cervical carcinoma patients
Kaplan-Meier 5-year survival curves and log rank ana-
lyses showed significant differences in the survival rates
between low and high TK1 LI patients in the total TK1
group (Figure 2D), cytoplasmic/nuclear TK1 group
(Figure 2E), and TK1 intensity groups (Figure 2F), and
Ki-67 (Figure 2C) group (Tab. 4). The significant value of
the cytoplasmic/nuclear TK1 group was higher compared
with the total TK1 group (Tab. 4, Figure 2D and E).Survival of invasive cervical carcinoma patients
There was a significant difference in the survival of
patients with low and high TK1 LI in the cytoplasmic/
nuclear TK1 group, and also in the total TK1 group, but
not in the Ki-67 group (Table 4). The survival curves were
very similar for those of the CIN III and invasive cervicalcarcinoma (see Figure 2), and thus we show the survival
curves of invasive cervical carcinoma patients alone.Survival of high-risk invasive carcinoma patients
There was a significant difference in the survival of
advanced-staged patients between the low and high TK1
LI patients groups (pathological stage III, X2 = 10.25,
p = 0.001, n = 33; FIGO stages IIB – IV, X2 = 8.78,
p = 0.009, n = 48) (Figure 2G, 2H). The survival rate of
the low TK1 LI group was about 80%, compared with
about 40% for the patients with high TK1 LI. There was
also a significant difference in the survival for total TK
LI, at least in the FIGO classification, between low and
high TK1 LI (pathological stage III, X2 = 2.65, p = 0.102,
FIGO stages IIB – IV, X2 = 4.19, p = 0.041). No such dif-
ferences were found between low and high Ki-67 LI
groups (pathological stage III, X2 = 0.196, p = 0.658; FIGO
stages IIB – IV, X2 = 1.75 p = 0.186). The percentage of
patients with better survival in the advanced tumor group
was 54.5%, based on the cytoplasmic/nuclear TK1 LI. On
the contrary, in the low risk group of invasive carcinoma,
there was no difference in the survival between the low
and high TK1 LI groups (cytoplasmic/nuclear LI) (patho-
logical stage II, X2 = 0.047, p = 0.828; FIGO stages IA- IIA,
X2 = 1.514, p = 0.219) or in the low and high Ki-67 LI
groups (pathological stage, X2 = 0.093, p = 0.760; FIGO
stages IA-IIA, X2 = 0.028, p = 0.866). These results suggest
that it is possible to identify patients in the advanced tumor
group that still have a good prognosis.COX uni- and multivariate analyses
As no CIN I and CIN II patients died, survival and COX
uni- and multivariate analyses could not be performed
on this group of patients. The prognostic factors that
showed significance in the univariate COX analysis were
further tested by the multivariate COX analysis. The COX
uni- and multivariate analyses were performed on all pa-
tients with cervical carcinoma, i.e. CIN III (carcinoma in
situ, n=45) and invasive cervical carcinoma (n =61) as one
group, or on invasive cervical carcinoma alone (n =61)
(Table 4). The results from the univariate analysis are
not shown.
Of the variable prognostic factors studied (pathological
stages, FIGO stages, TK1 [TK1 total expression, cyto-
plasmic/nuclear expression], Ki-67 and age), CIN III ver-
sus pathological stage II, FIGO stages 0 versus IA – IIA,
total TK1 and cytoplasmic/nuclear TK1 type of expres-
sion were found to be independent prognostic factors
(Table 4). In a corresponding COX analysis of the invasive
cervical carcinoma patients alone (pathological stages II
and III, n = 61, FIGO stages IA+IIA and IIB+IV, n = 61),
only cytoplasmic and nuclear TK1 expression was found to
be an independent prognostic factor for survival (Table 4).
Table 4 Log rank and Cox multivariate analysis of Kaplan-Mayer survival curves of CIN III and invasive cervical
carcinomas patients
Log rank Multivariate
Variable X2 DF P Hazard risk 95% CI P
CIN III + invasive CA (n=106)
"Total TK1" 8.60 1 0.003 3.30 1.3 – 8.8 0.015
"Cyto+nucl TK1" 11.39 1 <0.001 4.30 1.7 – 10.9 0.002
Ki-67 4.13 1 0.042 nd nd 0.541
Pathological stages:
0 versus II 12.51 1 <0.001 6.53 1.35-31.38 0.020
0 versus III 7.315 1 0,007 nd nd 0.065
FIGO stages:
0 versus IA-IIA 13.23 1 <0.001 9.19 1.68-50.35 0.011
0 versus IIB-IV 9.47 1 0.002 nd nd 0.060
Age 0.25 1 0.873 nd nd 0.160
Invasive CA (n=61)
"Total TK1" 3.51 1 0,061 nd nd 0.060
"Cyto+nucl TK1" 6.59 1 0,01 7.19 1.7– 29.7 0.015
Ki-67 0.00 1 0.999 nd nd 0.468
FIGO stages IA+IIA versus IIB+IV 0.44 1 0.509 nd nd 0.889
Pathological stage II versus III 0.91 1 0.329 nd nd 0.280
Age 2.27 1 0.132 nd nd 0.180
CA = carcinoma ; cyto = cytoplasma; nucl = nuclear; df = degree of freedom; nd = no data.
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In this study investigating on the expression of TK1 in
pre-malignant and malignant neoplasms of the cervix,
TK1 LI was found to be a more reliable prognostic marker
for 5-year survival than pathological stages, FIGO stages
and Ki-67, as demonstrated by LI and 5-year survival data.
COX multivariate hazard analysis also shows that the ex-
pression of TK1 in the nuclei of tumor cells is a markedly
independent prognostic factor for both CIN III and in-
vasive cervical carcinoma patients, while Ki-67 was not.
Thus, nuclear TK1 expression is a reliable prognostic fac-
tor in CIN patients, a group of cervical lesion patients that
respond positively to treatment. Furthermore, since nu-
clear TK1 expression is correlated with advanced stage of
invasive cervical carcinomas (pathological stage III/FIGO
stage IIA – IV), a low TK1 LI can help to identify with a
better survival. Thus, the low TK1 expression in the tu-
mors in these patients might indicate that these tumors
have a lower proliferation rate, and may be advantageous
for patient survival. Further studies may help determine if
less aggressive therapy may be tried to reduce treatment
morbidities for these patients.
TK1 is a key kinase in the one-step salvage pathway by
which thymidine is introduced into DNA via the salvage
pathway [19]. Thus, TK1 participates in DNA synthesis
and is therefore closely related to the S-phase of the cell
cycle, and is correlated with proliferation [18-21,24]. Animportant observation in this study is that the TK1 in-
tensity (TK1 synthesis rate) increases from CIN grade I
to CIN grade III, but does not further increase in inva-
sive cervical carcinomas. Thus, TK1 intensity seems to
be a prognostic factor particularly when pre-malignant
cervical lesions progress to malignancy. Although the
intensity of TK1 expression is not an independent prog-
nostic factor, it may be of benefit to use both the LI
of TK1 and the intensity of the TK1 expression when
judging the prognosis of pre-malignant patients, particular
in the earlier stages of CIN patients (CIN I and CIN II).
The significant correlation between TK1 LI and TK1 in-
tensity shows that higher numbers of proliferating tumor
cells are linked to an elevated synthesis rate of TK1. TK1
intensity has similarly been found in other studies to be a
prognostic factor in RCC patients [18].
TK1 expression was originally found in the cytoplasm
of cells growing in vitro (cell lines) [12,24]. TK1 expres-
sion was, subsequently, also found in nuclei of different
types of tumor tissues [12 – 18]. The reason why TK1 is
expressed in the nucleus is still debated, but it has been
suggested that this may be result from an elevated con-
centration of TK1 in the cytoplasm. It has also been sug-
gested that nuclear TK1 is involved in the repair of DNA
[25]. In this study, the ratio of nuclear TK1 to cytoplasmic
TK1 increases from CIN grade I to CIN grade III, indicat-
ing that nuclear TK1 is not due to increasing concentration
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DNA repair. This is supported by the fact that the survival
of patients with high nuclear TK1 expression is signifi-
cantly less compared to patients with low nuclear TK1 ex-
pression and high cytoplasmic expression. Efficient repair
of damaged DNA, caused by the chemo and/or radiation
therapy, may enhance the survival of tumor cells, but re-
duce patient survival. In addition, the expression of TK1 in
the nucleus is the strongest independent prognostic factor
in this study.
In this study two patients with CIN III died. Both pa-
tients showed high total TK1 LI (80%) and high cyto-
plasmic/nuclear TK1 LI (60%) and also a high score of
intensity TK1 (score 3). Ki-67 only gave a high LI value
in one of the patients and there was no difference in the
Ki-67 intensity. Further studies of CIN III may help deter-
mine if nuclear TK1 expression is helpful for clinical deci-
sion regarding the treatment of individual patients with
CIN III. Early discovery of pre-malignancy combined with
appropriate treatment may promote a better outcome.
The Pap smear and HPV DNA test can reveal abnor-
mal epithelial cells or presence of high-risk HPV, but
these tests do not assess the proliferation rate of cells,
which is an important factor for the development of can-
cer in later life. Nuclear TK1 expression in patients with
CIN grade I to III can provide reliable proliferation rate
information that is useful for early risk assessment of can-
cer progression and treatment choices for individuals.
This is a pure immunohistochemical study without mo-
lecular work-up, which may limited the understanding
of the biological aspects of the findings. Nonetheless, the
results do suggest possible application of the findings in
clinical management of patients with CIN and cervical
cancer. In addition, the possibility to identify patients with
better survival by “just” TK1 immunohistochemistry shows
the potential of immunostaining techniques alone.Conclusion
Nuclear TK1 expression in tumor cells of cervical lesions is
an independent prognostic factor, and is important for the
judgment of the prognosis of CIN patients, and invasive cer-
vical carcinoma patients. Nuclear TK1 expression is associ-
ated with aggressive features of cancer, as demonstrated by
its prognostic significance in terms of 5-year survival rates.Competing interests
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